Rhenman & Partners Asset Management Ab Denali Therapeutics Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $840 Million
- Q1 2025
A detailed history of Rhenman & Partners Asset Management Ab transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 100,000 shares of DNLI stock, worth $1.42 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
100,000Holding current value
$1.42 Million% of portfolio
0.16%Shares
1 transactions
Others Institutions Holding DNLI
# of Institutions
234Shares Held
127MCall Options Held
37.3KPut Options Held
7.9K-
Black Rock Inc. New York, NY13.2MShares$187 Million0.01% of portfolio
-
Baillie Gifford & CO12.1MShares$172 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$168 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA11.4MShares$162 Million0.03% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.77MShares$96.2 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $1.91B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...